Advanced search
Add to list

Scheduled maintenance: Publication downloads temporarily unavailable.

Due to maintenance publication downloads will not be available on:

  • Wednesday, March 27, 17:00 – 21:00
  • Thursday, March 28, 17:00 – 21:00

Exports of lists, FWO and BOF information will remain available.

For any questions, please contact biblio@ugent.be. Apologies for any inconveniences, and thank you for your understanding.

10-years' experience of aortic valve replacement with the Mitroflow bioprosthesis

Jonas Verbeke (UGent) , Liesbeth Lootens (UGent) , Thomas Martens (UGent) , Frank Caes (UGent) , Yves Van Belleghem (UGent) , Thierry Bové (UGent) and Katrien Francois (UGent)
Author
Organization
Abstract
Objective: Recent reports raised concerns on the durability of the Mitroflow aortic bioprosthesis, especially for the LXA-model without anticalcification treatment. This study reflects a single-center experience with the Mitroflow for aortic valve replacement (AVR). Method: From June 2003 to December 2014, 634 patients underwent AVR with the Mitroflow prosthesis. The study focused on 510 consecutive patients that received the LXA-prosthesis (2003-2012), by addressing the end-points survival and prosthesis durability, with structural valve degeneration (SVD) defined by a mean transprosthetic gradient > 30 mmHg at echocardiography and/or need for reoperation. Results: The mean patient age was 76±6 years, with 14% < 70 y and 23% > 80 y. Valve sizes 23 and 25 were used in 70%, and 19 and 21 in only 18%, avoiding patient-prosthesis mismatch (PPM) in 91%. The mean follow-up time was 5.0±3.2 years, cumulating a total of 2152 patient-years (max 11.6 y). The 1-, 5-, and 8-year patient survival was 86±2%, 67±3%, and 47±3 % respectively. Freedom from SVD was 99±1% and 88±3 % at 5 and 8 years. Reoperation for SVD was performed in 3.3%, including redo-AVR (9) or TAVI (6) for cusp rupture (6) and stenotic calcified degeneration (9). Prosthetic explantation for endocarditis was done in 3 patients. No specific patient- nor prosthesis-related factors significantly affected valve durability. SVD was not observed with the more recent Mitroflow model-DLA with phospholipid reduction therapy (used since May 2012), within a maximal follow-up time of 2.8 y. Conclusion: Despite lacking anticalcification treatment, the LXA-generation Mitroflow bioprosthesis offered a reliable aortic valve substitute in patients older than 70 years. The low occurrence of PPM, enhanced by its specific design and a consistent supra-annular implantation technique, might have improved the valve durability. Further results with the Mitroflow model-DLA have to be awaited.
Keywords
AVR, aortic valve replacement, Mitroflow, anticalcification, structural valve degeneration, LXA

Citation

Please use this url to cite or link to this publication:

MLA
Verbeke, Jonas, et al. “10-Years’ Experience of Aortic Valve Replacement with the Mitroflow Bioprosthesis.” BACTS 20th Congress, Abstracts, Belgian Association for Cardio-Thoracic Surgery (BACTS), 2015.
APA
Verbeke, J., Lootens, L., Martens, T., Caes, F., Van Belleghem, Y., Bové, T., & Francois, K. (2015). 10-years’ experience of aortic valve replacement with the Mitroflow bioprosthesis. BACTS 20th Congress, Abstracts. Presented at the BACTS 20th Congress, Brussels, Belgium.
Chicago author-date
Verbeke, Jonas, Liesbeth Lootens, Thomas Martens, Frank Caes, Yves Van Belleghem, Thierry Bové, and Katrien Francois. 2015. “10-Years’ Experience of Aortic Valve Replacement with the Mitroflow Bioprosthesis.” In BACTS 20th Congress, Abstracts. Belgian Association for Cardio-Thoracic Surgery (BACTS).
Chicago author-date (all authors)
Verbeke, Jonas, Liesbeth Lootens, Thomas Martens, Frank Caes, Yves Van Belleghem, Thierry Bové, and Katrien Francois. 2015. “10-Years’ Experience of Aortic Valve Replacement with the Mitroflow Bioprosthesis.” In BACTS 20th Congress, Abstracts. Belgian Association for Cardio-Thoracic Surgery (BACTS).
Vancouver
1.
Verbeke J, Lootens L, Martens T, Caes F, Van Belleghem Y, Bové T, et al. 10-years’ experience of aortic valve replacement with the Mitroflow bioprosthesis. In: BACTS 20th congress, Abstracts. Belgian Association for Cardio-Thoracic Surgery (BACTS); 2015.
IEEE
[1]
J. Verbeke et al., “10-years’ experience of aortic valve replacement with the Mitroflow bioprosthesis,” in BACTS 20th congress, Abstracts, Brussels, Belgium, 2015.
@inproceedings{6983086,
  abstract     = {{Objective: Recent reports raised concerns on the durability of the Mitroflow aortic bioprosthesis, especially for the LXA-model without anticalcification treatment. This study reflects a single-center experience with the Mitroflow for aortic valve replacement (AVR).
Method: From June 2003 to December 2014, 634 patients underwent AVR with the Mitroflow prosthesis. The study focused on 510 consecutive patients that received the LXA-prosthesis (2003-2012), by addressing the end-points survival and prosthesis durability, with structural valve degeneration (SVD) defined by a mean transprosthetic  gradient > 30 mmHg at echocardiography and/or need for reoperation.
Results: The mean patient age was 76±6 years, with 14% < 70 y and 23% > 80 y. Valve sizes 23 and 25 were used in 70%, and 19 and 21 in only 18%, avoiding patient-prosthesis mismatch (PPM) in 91%. The mean follow-up time was 5.0±3.2 years, cumulating a total of 2152 patient-years (max 11.6 y). The 1-, 5-, and 8-year patient survival was 86±2%, 67±3%, and 47±3 % respectively. Freedom from SVD was 99±1% and 88±3 % at 5 and 8 years. Reoperation for SVD was performed in 3.3%, including redo-AVR (9) or TAVI (6) for cusp rupture (6) and stenotic calcified degeneration (9). Prosthetic explantation for endocarditis was done in 3 patients. No specific patient- nor prosthesis-related factors significantly affected valve durability. SVD was not observed with the more recent Mitroflow model-DLA with phospholipid reduction therapy (used since May 2012), within a maximal follow-up time of 2.8 y.
Conclusion: Despite lacking anticalcification treatment, the LXA-generation Mitroflow bioprosthesis offered a reliable aortic valve substitute in patients older than 70 years. The low occurrence of PPM, enhanced by its specific design and a consistent supra-annular implantation technique, might have improved the valve durability. Further results with the Mitroflow model-DLA have to be awaited.}},
  author       = {{Verbeke, Jonas and Lootens, Liesbeth and Martens, Thomas and Caes, Frank and Van Belleghem, Yves and Bové, Thierry and Francois, Katrien}},
  booktitle    = {{BACTS 20th congress, Abstracts}},
  keywords     = {{AVR,aortic valve replacement,Mitroflow,anticalcification,structural valve degeneration,LXA}},
  language     = {{eng}},
  location     = {{Brussels, Belgium}},
  publisher    = {{Belgian Association for Cardio-Thoracic Surgery (BACTS)}},
  title        = {{10-years' experience of aortic valve replacement with the Mitroflow bioprosthesis}},
  year         = {{2015}},
}